Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate a Contact Lens Lubricating and Rewetting Drop

Not Applicable

Completed

Conditions: Dry Eye

Interventions: Device: Lubricating and Rewetting Drops
Device: AMO Blink Contacts Lubricant Eye Drops

First Posted Date: 2010-12-28

Last Posted Date: 2020-09-30

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 168

Registration Number: NCT01267656

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Co-Axial Micro-Incision Versus Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System

Phase 4

Completed

Conditions: Cataract
Aphakia

Interventions: Procedure: Coaxial Micro-Incision Cataract Surgery
Procedure: Coaxial Small Incision Cataract Surgery

First Posted Date: 2010-12-17

Last Posted Date: 2012-02-27

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 36

Registration Number: NCT01261975

Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses

Phase 4

Terminated

Conditions: Cataract

Interventions: Device: Crystalens AO
Device: SoftPort LI61AO

First Posted Date: 2010-11-16

Last Posted Date: 2014-11-26

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 6

Registration Number: NCT01241279

Locations: 🇺🇸
Bausch & Lomb, Irvine, California, United States

Product Performance of a Daily Disposable Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Daily disposable cosmetic tint lens

First Posted Date: 2010-10-29

Last Posted Date: 2019-08-28

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 212

Registration Number: NCT01230554

Locations: 🇸🇬
Bausch & Lomb, Singapore, Singapore

One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction

Phase 3

Completed

Conditions: Aphakia
Cataract

Interventions: Device: enVista

First Posted Date: 2010-10-28

Last Posted Date: 2013-08-22

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 122

Registration Number: NCT01230060

Locations: 🇺🇸
Bausch & Lomb, Aliso Viejo, California, United States

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: Mapracorat
Drug: Vehicle

First Posted Date: 2010-10-28

Last Posted Date: 2020-09-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 311

Registration Number: NCT01230125

Locations: 🇺🇸
Bausch & Lomb, Incorporated, Rochester, New York, United States

Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction

Phase 4

Completed

Conditions: Cataract

Interventions: Device: ReSTOR 3.0
Device: Crystalens AO
Device: AMO Tecnis Multifocal

First Posted Date: 2010-10-21

Last Posted Date: 2013-01-18

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 93

Registration Number: NCT01225952

Locations: 🇵🇭
Asian Eye Institute, Makati City, Philippines

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Intraocular Pressure

Interventions: Drug: BOL-303259-X
Drug: Latanoprost

First Posted Date: 2010-10-19

Last Posted Date: 2018-07-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 413

Registration Number: NCT01223378

Locations: 🇺🇸
Bausch & Lomb, Inc, Rochester, New York, United States

Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

Phase 1

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: bepotastine besilate nasal product - medium dose
Drug: bepotastine besilate nasal product - high dose
Drug: placebo comparator nasal product
Drug: bepotastine besilate nasal product - low dose

First Posted Date: 2010-10-18

Last Posted Date: 2020-10-05

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 89

Registration Number: NCT01222299

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Bromfenac Ophthalmic Solution A
Drug: Bromfenac Ophthalmic Solution B
Drug: Placebo Comparator

First Posted Date: 2010-09-30

Last Posted Date: 2020-09-04

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 840

Registration Number: NCT01212471

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy